EPTN marks a decade of European particle therapy collaboration and sets its next priorities
After 10 years, EPTN is shifting its focus toward prospective registries, adaptive therapy, harmonised QA and stronger clinical evidence.
After 10 years, EPTN is shifting its focus toward prospective registries, adaptive therapy, harmonised QA and stronger clinical evidence.
A portable 49 mT MRI system operated during proton and carbon-ion delivery with stable imaging and minimal dosimetric impact.
Upright gantry-less RT could reduce system complexity and improve access, but imaging, immobilization and limited clinical evidence remain major barriers.
Modern dosimetry can meet historical accuracy requirements, but tighter geometric precision and particle-specific uncertainties increasingly determine treatment accuracy.
Protons, helium and carbon ions suppressed migration and invasion that increased after photon irradiation, with helium showing a favorable biological-dosimetric balance.
Carbon ions show the strongest signal in radioresistant gynecologic tumors, while proton evidence centers on adjuvant treatment and reirradiation.
AI can automate particle planning, dose prediction, adaptation and quality assurance, but limited data and validation still constrain clinical adoption.
NanOx predictions differed from measured laryngeal cancer cell survival by 20–37% and overestimated the distal biological gradient.
A scanned helium beamline achieved submillimetre range accuracy and generally ≤3% dose agreement, supporting further translation toward clinical helium therapy.
Radioactive carbon-11 beams enabled PET-guided range adjustment during irradiation, with biological outcomes matching insufficient, optimal and excessive beam penetration.
A translational review proposes shared reporting and quality-assurance principles for model-dependent biological dose in proton, carbon-ion and boron neutron capture therapy.
Only 12 eligible studies were found, with inconsistent methods and assumptions that limited meaningful comparison of particle therapy costs.
Oxygen-ion irradiation showed higher biological effectiveness and more persistent DNA damage than carbon ions or photons in pancreatic cancer cells.